Effects of long-term PPI treatment on producing bowel symptoms and SIBO

European Journal of Clinical Investigation

Volumn 41, Issue 4, 2011, Pages 380-386

  Compare, Debora ^a   Pica, Loredana ^a   Rocco, Alba ^a   De Giorgi, Francesco ^a   Cuomo, Rosario ^a   Sarnelli, Giovanni ^a   Romano, Marco ^b   Nardone, Gerardo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

GERD; IBS; NERD; PPIs; SIBO

Indexed keywords

ESOMEPRAZOLE;

ABDOMINAL PAIN; ADULT; ARTICLE; BACTERIAL OVERGROWTH; BLOATING; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIGESTIVE TRACT ENDOSCOPY; DISEASE SEVERITY; FEMALE; FLATULENCE; HUMAN; HYDROGEN BREATH TEST; INCIDENCE; IRRITABLE COLON; MALE; NON EROSIVE REFLUX DISEASE; PH MEASUREMENT; POST HOC ANALYSIS; PRIORITY JOURNAL; SMALL INTESTINE DISEASE; STRUCTURED QUESTIONNAIRE;

ADULT; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; INTESTINES; IRRITABLE BOWEL SYNDROME; ITALY; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMP INHIBITORS; TIME FACTORS;

EID: 79952499261     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2010.02419.x     Document Type: Article

References (45)

1. Hansen JM, Wildner-Christensen M, Schaffalitzky de Muckadell OB. Gastroesophageal reflux symptoms in a Danish population: a prospective follow-up analysis of symptoms, quality of life and health-care use. Am J Gastroenterol 2009;104:2394-403.
2. Isolauri J, Laippala P. Prevalence of symptoms suggestive of gastro-oesophageal reflux disease in an adult population. Ann Med 1995;27:67-70.
3. Valle C, Broglia F, Pistorio A, Tinelli C, Perego M. Prevalence and impact of symptoms suggestive of gastroesophageal reflux disease. Dig Dis Sci 1999;44:1848-52.
4. Körner T, Schütze K, van Leendert RJ, Fumagalli I, Costa Neves B, Bohuschke M et al. Comparable efficacy of pantoprazole and omeprazole in patients with moderate to severe reflux esophagitis. Results of a multinational study. Digestion 2003;67:6-13.
5. Gillessen A, Beil W, Modlin IM, Gatz G, Hole U. 40mg pantoprazole and 40mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptoms. J Clin Gastroenterol 2004;38:332-40.
6. Scholten T, Gatz G, Hole U. Once-daily pantoprazole 40mg and esomeprazole 40mg have equivalent overall efficacy in relieving GERD-related symptoms. Aliment Pharmacol Ther 2003;18:587-94.
7. Piterman L, Nelson M, Dent J. Gastro-oesophageal reflux disease: current concepts in management. Aust Fam Physician 2004;33:987-91.
8. Bak YT. Management strategies for gastroesophageal reflux disease. J Gastroenterol Hepatol 2004;19(Suppl. 3):S49-53.
9. Plein K, Hotz J, Wurzer H, Fumagalli I, Lühmann R, Schneider A. Pantoprazole 20mg is an effective maintenance therapy for patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2000;12:425-32.
10. Johnson DA, Benjamin SB, Vakil NB, Goldstein JL, Lamet M, Whipple J et al. Esomeprazole once daily for 6months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol 2001;96:27-34.
11. Relly JP. Safety profile of the proton pump inhibitors. Am J Health Syst Pharm 1999;56:S11-7.
12. Bateman DN, Colin-Jones D, Hartz S, Langman M, Logan RF, Mant J et al. Mortality study of 18, 000 patients treated with omeprazole. Gut 2003;52:942-6.
13. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk in PPI. Am J Gastroenterol 2009;104(Suppl. 2):S27-32.
14. 2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol 2004;57:422-8.
15. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007;102:2047-56.
16. Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007;167:950-5.
17. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296:2947-53.
18. Williams C, McColl KE. Review article: proton pump inhibitors and bacterial overgrowth. Aliment Pharmacol Ther 2006;23:3-10.
19. Howden CW, Hunt RH. Relationship between gastric secretion and infection. Gut 1987;28:96-107.
20. Laine L, Ahnen D, McClain C, Solcia E, Walsh JH. Review article: potential effects of long-term acid suppression with PPIs. Aliment Pharmacol Ther 2000;14:651-68.
21. Martinez SD, Malagon IB, Garewal HS, Cui H, Fass R. Non-erosive reflux disease (NERD)-acid reflux and symptom patterns. Aliment Pharmacol Ther 2003;17:537-45.
22. Dean BB, Gano AD Jr, Knight K, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in non-erosive reflux disease. Clin Gastroenterol Hepatol 2004;2:656-64.
23. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006;130:1480-91.
24. Armstrong D, Bennett JR, Blum AL, Dent J, De Dombal FT, Galmiche JP et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology 1996;111:85-92.
25. Bancewicz J, Matthews HR, O'Hanrahan T. A comparison of surgically treated reflux patients in two surgical centers. In: Little AG, Ferguson MK, Skinner DB, editors. Diseases of the Esophagus. New York: Futura, 1990:177-80.
26. Cuomo R, De Giorgi F, Adinolfi L, Sarnelli G, Loffredo F, Efficie E et al. Oesophageal acid exposure and altered neurocardiac function in patients with GERD and idiopathic cardiac dysrhythmias. Aliment Pharmacol Ther 2006;24:361-70.
27. Gasbarrini A, Corazza GR, Gasbarrini G, Montalto M, Di Stefano M, Basilisco G et al. 1st Rome H2-Breath Testing Consensus Conference Working Group. Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference. Aliment Pharmacol Ther 2009;29(Suppl. 1):1-49.
28. Locke GR, Zinsmeister AR, Talley N, Fett SL, Melton LJ III. Familial association in adults with functional gastrointestinal disorders. Mayo Clin Proc 2000;75:907-12.
29. Nastaskin I, Mehdikhani E, Conklin J, Park S, Pimentel M. Studying the overlap between IBS and GERD: a systematic review of the literature. Dig Dis Sci 2006;51:2113-20.
30. Zimmerman J, Hershcovici T. Bowel symptoms in nonerosive gastroesophageal reflux disease: nature, prevalence, and relation to acid reflux. J Clin Gastroenterol 2008;42:261-5.
31. Theodoropoulos DS, Pecoraro DL, Lockey RF, Boyce HW Jr, Bukantz SC. Visceral sensitivity in gastroesophageal reflux. Dig Dis Sci 2002;47:2554-64.
32. Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995;109:40-52.
33. Spiegel BM, Chey WD, Chang L. Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors? Am J Gastroenterol 2008;103:2972-6.
34. Chey WD, Spiegel B. Proton pump inhibitors, irritable bowel syndrome, and small intestinal bacterial overgrowth: coincidence or Newton's third law revisited? Clin Gastroenterol Hepatol 2010;8:480-2.
35. Majewski M, McCallum RW. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial. Adv Med Sci 2007;52:139-42.
36. Verdú EF, Armstrong D, Fraser R, Viani F, Idström JP, Cederberg C et al. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 1995;36:539-43.
37. Stockbruegger RW, Cotton PB, Eugenides N, Bartholomew BA, Hill MJ, Walters CL. Intragastric nitrites, nitrosamines and bacterial overgrowth during cimetidine treatment. Gut 1982;23:1048-54.
38. Thomas JM, Misiewicz JJ, Cook AR, Hill MJ, Smith PL, Walters CL et al. Effects of one year's treatment with ranitidine and of truncal vagotomy on gastric contents. Gut 1987;28:726-38.
39. Thorens J, Froehlich F, Schwizer W, Saraga E, Bille J, Gyr K et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut 1996;39:54-9.
40. Fried M, Siegrist H, Frei R, Froehlich F, Duroux P, Thorens J et al. Duodenal bacterial overgrowth during treatment in outpatients with omeprazole. Gut 1994;35:23-6.
41. Lewis SJ, Franco S, Young G, O'Keefe SJ. Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Aliment Pharmacol Ther 1996;10:557-61.
42. Hutchinson S, Logan R. The effect of long-term omeprazole on the glucose-hydrogen breath test in elderly patients. Age Ageing 1997;26:87-9.
43. Pereira SP, Gainsborough N, Dowling RH. Drug-induced hypochlorhydria causes high duodenal bacterial counts in the elderly. Aliment Pharmacol Ther 1998;12:99-104.
44. Nelis GF, Engelage AH, Samson G. Does long-term inhibition of gastric acid secretion with omeprazole lead to small intestinal bacterial overgrowth? Neth J Med 1994;45:93-100.
45. Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during Proton Pump Inhibitor therapy. Clin Gastroenterol Hepatol 2010;8:504-8.